MapLight Therapeutics stock crashes on Phase II schizophrenia data
MapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.
How this was made
The 30-second read
Why it matters
The mixed Phase II schizophrenia data appears to have triggered a sharp de-risking of the ZEPHYR program, driving a large one-week drawdown.
Market read
Traders are likely repricing MAPS’s clinical probability and near-term financing risk after a mixed Phase II readout.
What to watch
The article lacks the specific efficacy and safety endpoints, effect sizes, and whether the data supports protocol amendments, which are key to judging how durable the repricing should be.
Background
MapLight debuted on Nasdaq in Oct 2025 after a $250m IPO to fund the ZEPHYR trial, and it is positioning itself against BMS’s Cobenfy in schizophrenia.
Market effects
Highlights how schizophrenia pipeline readouts can rapidly reset expectations for atypical antipsychotic competitors and trial timelines.
Primarily US-listed small-cap biotech sentiment; limited broader regional spillover implied.
GlobalData’s market sizing for schizophrenia is cited, but the actionable shock is company-specific to MapLight’s trial outcome.
Counterpoint
A “mixed” Phase II result can still support a path forward (e.g., subgroup signals or safety tolerability), so the selloff may over-discount without endpoint detail.
Key entities
- companyMapLight Therapeutics
Subject of the article; its Phase II schizophrenia data was followed by a 71.9% stock drop.
- companyBristol Myers Squibb
Cobenfy competitor mentioned as having FDA approval in Sept 2024.
- productCobenfy (xanomeline and trospium chloride)
FDA-approved schizophrenia drug used as the competitive benchmark in the article.
- clinical_programZEPHYR trial
MapLight’s trial funded by its IPO, referenced as the program behind the Phase II readout.
- research_firmGlobalData
Provides schizophrenia market forecasts and pipeline share assumptions cited in the article.